Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas
Peter Martin(Northwestern University), John P. Leonard(New York University), Morton Coleman(Cornell University), Scott Ely(NewYork–Presbyterian Hospital), Sarah C. Rutherford(NewYork–Presbyterian Hospital), Stanley J. Goldsmith(United States Department of Health and Human Services), Richard R. Furman(Cornell University), June Greenberg(Cornell University), Jia Ruan(Cornell University)
Cited by 49
Related Papers
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k